Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatment
Authors' conclusion
The initiation of newer AOMs among overweight and obese populations remains low, but uptake has increased exponentially since 2022. Our findings reveal significant disparities in obesity care, highlighting the importance of addressing inequities in AOM access to improve obesity outcomes.
Study context
- Population
- Adults eligible for anti-obesity medications (AOMs) (body mass index (BMI) ≥30 kg/m², or BMI 27–29.9 kg/m² with ≥1 obesity-related comorbidity), OneFlorida+ EHR data 2015–2024
- Participants
- 319,949 adults
- Exposure
- Factors associated with initiation of newer AOMs
- Outcome
- Initiation of newer AOMs: GLP-1 RAs (liraglutide, semaglutide, tirzepatide)
Methodological detailselectronic health record data, multivariable logistic regression
- Electronic health record data
- Multivariable logistic regression
Main finding
As reported in the abstract
Initiation of newer AOMs
Adjusted odds ratio (95% CI)
Blackvs Whites
0.87(0.80–0.94)
Hispanicvs Whites
0.84(0.78–0.91)
Medicaidvs privately insured
0.69(0.63–0.76)
Uninsuredvs privately insured
0.81(0.74–0.87)
- Adults initiating newer AOMs
- 1.8%
Observational data: associations, not effects.
Further findings
Share of initiations by agent
- Semaglutide
- 77.9%
- Tirzepatide
- 19.7%
- Liraglutide
- 17.8%
Initiation trends
- Liraglutide uptake peaked in 2018, then declined
- 5%
- Semaglutide and tirzepatide uptake increased exponentially since 2022
Original publication
Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatment. Diabetes Obes Metab. Published 4 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →